Docket No: 235,00210101

DECLARATION

We, James Travis, Jan S. Potempa, and Daniel C. Nelson, declars that: (1) our respective citizenships and residence/mailing addresses are indicated below; (2) we have reviewed and understand the contents of the specification identified below, including the claims, as amended by any amendment specifically referred to herein. (3) we believe that we are the original, first, and joint inventors of the subject matter in

A POLYPEPTIDE HAVING AMIDOLYTIC ACTIVITY FOR A SERPIN

Filing Date: Even date herewith

Serial No.: Unknown

described and claimed therein and for which a patent is sought; and (4) we hereby acknowledge our duty to disclose to the United States Patent and Trademark Office all information known to us to be material to the patentability as defined in Title 37, Code of Federal Regulations, §1.56.*

We hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate listed below, or §365(a) of any PCT international application which designates at least one country other than the United States of America listed below, and have also identified below any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on the basis of which priority is claimed:

a. X no such applications have been filed.

= |-≟

b. __ such applications have been filed as follows:

| FOREI | GN APPLICATION(8), IF 35 USC §119(a)-(d) | ANY, CLAIMING PRIORI , §365(a), and/or §365(b) | TY UNDER |
|---------|---|---|-------------------------------------|
| COUNTRY | APPLICATION NUMBER | DATE OF FILING (day, month, year) | DATE OF ISSUE (day, month, year) |
| 0.0 | | | |

| ALL FOREIGN AP | PLICATIONS, IF ANY, F | ILED BEFORE THE PRIO | RITY APPLICATION(S) |
|----------------|-----------------------|--------------------------------------|-------------------------------------|
| COUNTRY | APPLICATION NUMBER | DATE OF FILING (day, month, year) | DATE OF ISSUE (day, month, year) |
| | | | |
| | | | |

^{*}Title 37, Code of Federal Regulations, \$1.56 is reproduced on the annuhal page

Applicants: James Travis, et al.

Serial No.: Unknown

Filing Date: Even date herewith

Tille: A POLYPEPTIDE HAVING AMIDOLYTIC ACTIVITY FOR A SERPIN

We hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

a. ___ no such applications have been filed.

b. X such applications have been filed as follows:

| PROVISIONAL APPLICATION(S |), IF ANY, UNDER 35 USC §119(e) |
|---------------------------|-----------------------------------|
| APPLICATION NUMBER | DATE OF FILING (day, month, year) |
| 60/130,436 | 21 April 1999 |
| | |

We hereby claim the benefit under Title 35, United States Code, § 120 of any United States applications or §365(c) of any PCT international application(s) designating the United States of America, listed below.

a. __ no such applications have been filed.

b. X such applications have been filed as follows:

| APPLICATION NUMBER | DATE OF FILING (day, month, year) | STATUS (patented, pending, abandoned) |
|--------------------|--------------------------------------|---------------------------------------|
| PCT/US00/10574 | 20 April 2000 | Pending |
| | | |

Insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, §112, we acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

The undersigned declare further that all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

TOOSOSSO TOISOI

Applicanis: James Travis, et al.

Serial No.: Unknown

Filing Date: Even date herewith

Title: A POLYPEPTIDE HAVING AMIDOLYTIC ACTIVITY FOR A SERPIN

Wherefore, we pray that Letters Pagent be granted to us for the invention described and claimed in the specification identified above and we hereby subsoribe our names to the foregoing specification, claims, and Declaration, on the date indicated below.

ames Travis

United States of America

GA

Residence:

825 Riverbend Parkway, Athens, Georgia 30605, USA

Mailing Address: Same as above (If different than Residence)

Name:

Jan S. Potempa

Citizenship:

United States of America

GA

Date

Date

Date

Residence:

170 Barrington Drive, Apt. #102, Athens, Georgia 30605, USA

Mailing Address: Same as above (If different than Residence)

Name:

Daniel C. Nelson

United States of America

504 - Bast 63rd Street, #20R, New York, New York 10021, USA

Mailing Address: Same as above (If different than Residence)

Citizenship: Residence:

Page 3 of 4

Pel 27/1

#

. П Applicants: James Travis, et al.

Serial No.: Unknown

Filing Date: Even date herewith

Title: A POLYPEPTIDE HAVING AMIDOLYTIC ACTIVITY FOR A SERPIN

§ 1.56 Duty to disclose information material to patentability.

- (a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:
 - (1) Prior art cited in search reports of a foreign patent office in a counterpart application, and
 - (2) The closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.
- (b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and
 - (1) It establishes, by itself or in combination with other information, a prima facie case of unpater tability of a claim; or
 - (2) It refutes, or is inconsistent with, a position the applicant takes in:
 - (i) Opposing an argument of unpatentability relied on by the Office, or
 - (ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

- (c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:
 - (1) Each inventor named in the application;
 - (2) Each attorney or agent who prepares or prosecutes the application; and
 - Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.
- (d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.
- (e) In any continuation-in-part application, the duty under this section includes the duty to disclose to the Office all information known to the person to be material to patentability, as defined in paragraph (b) of this section, which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

Docket No: 235.00210101

DECLARATION

We. James Travis, Jan S. Potempa, and Daniel C. Nelson, declars that: (1) our respective citizenships and residence/mailing addresses are indicated below; (2) we have reviewed and understand the contents of the specification identified below, including the claims, as amended by any amendment specifically referred to herein, (3) we believe that we are the original, first, and joint inventors of the subject matter in

A POLYPEPTIDE HAVING AMIDOLYTIC ACTIVITY FOR A SERPIN

Filing Date: Even date herewith

Serial No.: Unknown

described and claimed therein and for which a patent is sought; and (4) we hereby acknowledge our duty to disclose to the United States Patent and Trademark Office all information known to us to be material to the patentability as defined in Title

We hereby claim foreign priority benefits under Title 35, United States Code, \$119(a)-(d) or \$365(b) of any foreign application(s) for patent or inventor's certificate listed below, or \$365(a) of any PCT international application which designates at least one country other than the United States of America listed below, and have also identified below any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on the basis of which priority is claimed:

a. X no such applications have been filed.

b. __ such applications have been filed as follows:

| FORE | (GN APPLICATION(S), IF 35 USC §119(a)-(d) | ANY, CLAIMING PRIOR , §365(a), and/or §365(b) | ITY UNDER |
|----------------|--|--|----------------------------------|
| COUNTRY | APPLICATION NUMBER | DATE OF FILING (day, month, year) | DATE OF ISSUE (day, month, year) |
| ALL FOREIGN AP | PLICATIONS OF ANY ET | | |

| ALL FOREIGN AP | PLICATIONS, IF ANY, F | LED BEFORE THE PRIO | RITY APPLICATION(S) |
|----------------|-----------------------|-----------------------------------|-------------------------------------|
| COUNTRY | APPLICATION NUMBER | DATE OF FILING (day, month, year) | DATE OF ISSUE (day, month, year) |
| | | | |

Title 37. Code of Federal Regulations, §1.56 is reproduced on the attached page.

Applicants: James Travis, et al.

Serial No.: Unknown

Filing Date: Even date herewith

Title: A POLYPEPTIDE HAVING AMIDOLYTIC ACTIVITY FOR A SERPIN

We hereby claim the benefit under Title 35, United States Code §119(c) of any United States provisional application(s) listed below.

- no such applications have been filed.
- b. X such applications have been filed as follows:

| S), IF ANY, UNDER 35 USC §119(e) |
|-----------------------------------|
| DATE OF FILING (day, month, year) |
| 21 April 1999 |
| |

We hereby claim the benefit under Title 35, United States Code, §120 of any United States applications or §365(c) of any PCT international application(s) designating the United States of America, listed below.

- no such applications have been filed.
- b. X such applications have been filed as follows:

| APPLICATION NUMBER | DATE OF FILING (day, month, year) | STATUS (patented, pending, abandoned) |
|--------------------|--------------------------------------|--|
| PCT/US00/10574 | 20 April 2000 | Pending |
| | | |

Insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, §112, we acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

The undersigned declare further that all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Ш W Ö

| Declarution Applicants: James Serial No.: Unkno Filing Date: Even Tule: A POLYPEP | wn | |
|---|--|--|
| Wherefore identified above an indicated below. | e, we pray that Letters Patent be granted to us for the invention described and we hereby subscribe our names to the foregoing specification, claims | and claimed in the specification, and Declaration, on the date |
| Cinzenship: | James Travis United States of America 825 Riverbend Parkway, Athens, Georgia 30605, USA Same as above Residence | Date |
| Name: Citizenship: Residence: Mailing Address (If different than | Jan S. Potentpa United States of America 170 Barrington Drive, Apt. #102, Athens, Georgia 30605, USA Same as above Residence) | Date |
| Name: Citizenship: Residence: Mailing Address (If different than | Daniel C. Nelson United States of America 504 - East 63rd Street, #20R, New York, New York 10021, USA :: Same as above Residence) | Dai |

Page 3 of 4

 Page 4 of 4

Applicants: James Travis, et al.

Serial No.: Unknown

Filling Date: Even date herewith

Tale: A POLYPEPTIDE HAVING AMIDOLYTIC ACTIVITY FOR A SERPIN

§ 1.56 Duty to disclose information material to patentability.

A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

Prior art cited in search reports of a foreign patent office in a counterpart application, and (1)

The closest information over which individuals associated with the filing or prosecution of a patent (2) application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

- W **(b)** Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and 445
 - It establishes, by itself or in combination with other information, a prima facic case of unpatentability (1)
 - (2)it refutes, or is inconsistent with, a position the applicant takes in:
 - (i) Opposing an argument of unpatentability relied on by the Office, or
 - (ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

- Individuals associated with the filing or prosecution of a patent application within the meaning of this (c) section are:
 - Each inventor named in the application; (1)
 - (2) Each attorney or agent who prepares or prosecutes the application; and
 - Every other person who is substantively involved in the preparation or prosecution of the application and (3)who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.
- Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.
- In any continuation-in-part application, the duty under this section includes the duty to disclose to the Office all information known to the person to be material to patentability, as defined in paragraph (b) of this section, which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

Docket No: 235.00210101

DECLARATION

We, James Travis, Jan S. Potempa, and Daniel C. Nelson, declare that: (1) our respective citizenships and residence/mailing addresses are indicated below; (2) we have reviewed and understand the contents of the specification identified below, including the claims, as amended by any amendment specifically referred to herein, (3) we believe that we are the original, first, and joint inventors of the subject matter in

A POLYPEPTIDE HAVING AMIDOLYTIC ACTIVITY FOR A SERPIN

Filing Date: Even date herewith

Serial No.: Unknown

described and claimed therein and for which a patent is sought; and (4) we hereby acknowledge our duty to disclose to the United States Patent and Trademark Office all information known to us to be material to the patentability as defined in Title 37, Code of Federal Regulations, §1.56.*

We hereby claim foreign priority benefits under Title 35. United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate listed below, or §365(a) of any PCT international application which designates at least one country other than the United States of America listed below, and have also identified below any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on the basis of which priority is claimed:

a. X no such applications have been filed.

b. __ such applications have been filed as follows:

| FORE | GN APPLICATION(S), IF 35 USC §119(a)-(d) | ANY, CLAIMING PRIORI , §365(2), and/or §365(b) | TY UNDER |
|---------|---|---|-------------------------------------|
| COUNTRY | APPLICATION NUMBER | DATE OF FILING (day, month, year) | DATE OF ISSUE (day, month, year) |
| | | | |

| ALL FOREIGN AP | PLICATIONS, 1F ANY, F | ILED BEFORE THE PRIO | RITY APPLICATION(S) |
|----------------|-----------------------|--------------------------------------|-------------------------------------|
| COUNTRY | APPLICATION NUMBER | DATE OF FILING (day, month, year) | DATE OF ISSUE (day, month, year) |
| | | | |

Title 37, Code of Federal Regulations, §1.56 is reproduced on the attached page.

Applicants: James Travis, et al. Serial No.: Unknown

Filing Date: Even date herewith

Title: A POLYPEPTIDE HAVING AMIDOLYTIC ACTIVITY FOR A SERPIN

We hereby claim the benefit under Title 35, United States Code \$119(e) of any United States provisional application(s) listed below.

a. __ no such applications have been filed.

b. X such applications have been filed as follows:

| s), IF ANY, UNDER 35 USC §119(e) |
|--------------------------------------|
| DATE OF FILING (day, month, year) |
| 21 April 1999 |
| |

We hereby claim the benefit under Title 35, United States Code, §120 of any United States applications or §365(c) of any PCT international application(s) designating the United States of America, listed below.

a. ___ no such applications have been filed.

b. X such applications have been filed as follows:

| APPLICATION NUMBER | DATE OF FILING (day, month, year) | STATUS (patented, pending, abandoned) |
|--------------------|--------------------------------------|---------------------------------------|
| PC1/US00/10574 | 20 April 2000 | Pending |
| | | |

Insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, §112, we acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

The undersigned declare further that all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Page 3 of 4

Declaration

Applicants: James Travis, et al.

Serial No.: Unknown

Filing Date: Even date herewith

Title: A POLYPEPTIDE HAVING AMIDOLYTIC ACTIVITY FOR A SERPIN

Wherefore, we pray that Letters Patent be granted to us for the invention described and claimed in the specification identified above and we hereby subscribe our names to the foregoing specification, claims, and Declaration, on the date indicated below.

Name:

James Travis

Date

Citizenship:

United States of America

Residence:

825 Riverbend Parkway, Athens, Georgia 30605, USA

Mailing Address: Same as above (If different than Residence)

Name:

Ħ, Jan S. Potempa

Date

Citizenship:

United States of America

Residence:

170 Barrington Drive, Apt. #102, Athens, Georgia 30605, USA

Mailing Address: Same as above (If different than Residence)

Name:

Citizenship:

United States of America

Residence:

504 - East 63rd Street, #20R, New York, New York 10021, USA

Mailing Address: Same as above (If different than Residence)

Declaration
Applicants: Jumes Travis, et al.

Page 4 of 4

Senal No.: Unknown

Filing Date: Even date herewith

Title: A POLYPEPTIDE HAVING AMIDOLYTIC ACTIVITY FOR A SERPIN

§ 1.56 Duty to disclose information material to patentability.

- A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claimissued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:
 - (1) Prior art cited in search reports of a foreign patent office in a counterpart application, and
 - (2) The closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.
- (b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and
 - (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or
 - (2) It refutes, or is inconsistent with, a position the applicant takes in:
 - (i) Opposing an argument of unpatentability relied on by the Office, or
 - (ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

- (c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:
 - Each inventor named in the application;
 - (2) Bach attorney or agent who prepares or prosecutes the application; and
 - (3) Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.
- (d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.
- (c) In any continuation-in-part application, the duty under this section includes the duty to disclose to the Office all information known to the person to be material to patentability, as defined in paragraph (b) of this section, which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

ASSIGNMENT

Whereas We, James Travis, Jan Potempa, and Daniel Nelson, with residences and citizenships as indicated below; have made an invention in

A POLYPEPTIDE HAVING AMIDOLYTIC ACTIVITY FOR A SERPIN

International Application No. PCT/US00/10574, filed April 20, 2000 U.S. Provisional Applin. Serial No. 60/130,436, filed April 21, 1999

Now, therefore, for good and valuable consideration, receipt of which is acknowledged, we have individually and jointly agreed to assign and transfer and do hereby assign and transfer unto The University of Georgia Research Foundation. Inc. ("Company"), a corporation of GEORGIA, having its principal office at Hoyd Graduate Studies Research Center, Athens, Georgia 30602-7411, USA, its successors and assigns, the entire right, title, and interest in and to said invention and application, and in and to any division or continuation (in whole or in part) of said application, and in and to any and all improvements in said invention made by us or any of us or made jointly with others (provided tany such improvement is made during, or within one year after the termination of, the employment by the Company of whichever of us, solely or jointly with one or more others, has made the same), and in and to any and all Patents, reexaminations, reissues, or extensions thereof, of the United States of America and countries foreign thereto (including the right to apply for Patents, Utility Models, or Inventors' Certificates in foreign countries in its own name and to claim easy priority rights for such foreign applications to which such applications are entitled under international conventions, recaties, or otherwise), which have been or may be granted thereon or on any continued prosecution application, adivisional, continuation (in whole or in part), renewal, reexamination, reissue, or other or further application based in whole or in part upon said invention or improvements thereon, to be held and enjoyed as fully and exclusively as they would have been by us or any of us had this assignment and transfer not been made;

We do further agree for ourselves and for our heirs, executors, and administrators, to execute and deliver without further consideration any further applications, assignments, and documents, and to perform such other acts as we lawfully may, that may be deemed necessary by the Company, its successors, assigns, and nominees, fully to secure its right, title, and interest as aforesaid and to obtain or maintain Patents, Utility Models, or Inventors' Certificates in any and all countries;

the person described in and who executed the foregoing instrument, and he/she executed the same for the uses and

purposes therein set forth.

Page 3 of 3

day of the purposes therein set forth. On this 10 day of Othle 2000 before me personally appeared Daniel Nelson to me known to be the person described in and who executed the foregoing instrument, and he/she executed the same for the uses and

W

⊨

GLORIA CHANG DIGENNARO Notary Public, State of New York No. 4884704 Qualified in Westchester County Commission Expires Jan. 12, 2007